期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 17, 期 12, 页码 5148-5149出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2021.1991710
关键词
COVID-19; BNT162b2; cell-mediated immunity
Vaccines against SARS-CoV-2 have shown varied immunogenicity among individuals, with some having lower levels of antibody production and others exhibiting notably high levels. The study found that participants with high antibody levels demonstrated adequate cellular response, while those with low antibody levels generally showed limited to absent cellular response five months post vaccination.
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production. We assessed the cellular response to BNT162b2 among individuals with low post-vaccination antibody levels as well as in a small group of individuals with high titers. Antibody levels were assessed by the Abbott SARS-CoV-2 IgG II Quant assay. The interferon-gamma production of T-cells in response to SARS-CoV-2 antigens was determined using Qiagen's QuantiFERON SARS-CoV-2 ELISA test. Our results showed that participants with high antibody levels presented adequate cellular response in all studied cases, whereas those with low antibody levels generally showed limited to almost absent cellular response five months post vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据